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This entire session is based upon a fairly simple 
assumption that the state of the host immune 
system is an important factor in determining 
whether or not malignant tumors develop 
and/or with what aggressiveness the tumors 
grow and spread after their inception. The 
objective of the presentation is to report to 
you some observations that quite definitely 
support an immunologic hypothesis for the 
etiology of cancer. 
Surveillance and Infection 
It is axiomatic that some element of host 
immunologic crippling must be accepted as 
the price for success after renal transplantation. 
As a consequence, there is a definitely increas-
ed incidence of the kind of infection you see 
in Fig. 1. Shown is the brain of a heart 
recipient who died 4 months after operation. 
The lesion was caused by the fungus, Asper-
gillus Fumigatus. The sequence of events lead-
ing to this death could be envisioned as one 
Fig. 1: 
Fungus brain abscess in a patient who died more 
than four months after combined c::trdiac and renal 
transplant:ltion. 
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in which the recognition of the kidney as 
"non-self" was deliberately prevented and that 
the surveillance of a variety of inimical antigens 
was coincidently and unfortunately lost. 
Surveillance and Malignancy 
In the foregoing example, the weakening or 
loss of surveillance was to fungi or bacteria. 
It now seems established that the same thing 
applies with tumors. In 1968 we reported the 
first examples of this complication from the 
iatrogenic immunosuppression of renal reci-
pients. At that time an informal tumor 
registry was established in Denver. Contribu-
tions to this registry have been made from 
virtually every major transplantation center in 
the world. By last December, neoplasms in 74 
renal recipients had been compiled from our 
own program or else submitted by other groups 
to this registry. In addtion 1 patient had 
developed a carcinoma of the stomach follow-
ing heart transplantation. The incidence of this 
complication is truly amazing (Table 1). 
Table 1: 
Malignant Tumors in Renal Homograft Recipients 
(University of Colorado Series) 
Number of patients 
Number with tumors 
Incidence 
Number of deaths in first 4 months 
Number of patients at risk 
Corrected Incidence 
352 
16 
4.5 0/0 
66 
286 
5.6% 
It is not possible to give accurate figures 
based on the world experience since the exact 
number of malignancies and the numbers of 
patients at risk at various postoperative times 
are not known. However, there are accurate 
figures from our own renal transplantation 
senes. 
In this experience, as of last December, there 
were 16 patients who developed malignant 
tumors in 352 renal homograft recipients with 
potential followups of 6 months to 91/2 years. 
This incidence of 4.5 % does not reflect the 
true frequency of post-transplantation neo-
plasia since 66 patients died of a variety of 
other complications before the end of the fourth 
postoperative month. The 16 neoplasms devel-
oped in the remaining 286 patients for a parti-
ally corrected incidence of 5.6010 (Table 1). 
The rate of tumor development in these young 
patients (31/2 to 49 years, average less than 30 
years) compares with the yearly incidence of 
58 per 100,000 (0.058010) in the general popula-
tion in a comparable age range. Even if the 
half dozen skin tumors are excluded, which is 
sometimes done in compiling such cancer risk 
statistics, the corrected incidence of malignant 
disease in our series is still extraordinarily high. 
Now to turn to the world collection. Forty 
four of the tumors in the world collection were 
of epithelial origin (Table 2). The most common 
Table 2: 
Malignant Tumors in Organ Homograft Recipients 
(World Experience) 
Types of tumors 
I. Epithelial tumors 44 
Skin tumors 11 
Carcinoma in situ of cervix 8 
Carcinoma of lip 8 
Lung tumors 4 
Hepatoma 2 
Miscellaneous carCInomas 11 
epithelial tumors were carcinoma in situ of the 
cervix uteri (8 cases); squamous cell carcinoma 
of the lip (8 cases); and squamous or basal 
cell skin carcinomas (11 cases). Miscellaneous 
and generally more serious carcinomas made 
up the other half. 
The 32 mesenchymal tumors were a much more 
homogenous group in that 28 were varieties 
of lymphoma including 21 examples of reti-
culum cell sarcoma or malignant reticulosis. 
A variety of other sarcomas are listed in 
Table 3. 
Table 3: 
Malignant Tumors in Organ Homograft Recipients 
(World Experience) 
Types of tumors 
II. Mesenchymal tumors 
Reticulum cell sarcoma 
Lymphoma 
Kaposi's sarcoma 
Leiomyosarcoma 
Rhabdomyosarcoma 
Synovial sarcoma 
32':-
21 
4 
3 
2 
1 
1 
,:- Includes a patient with 2 tumors - a reticulum 
cell sarcoma of the brain and a Kaposi's sarcoma 
of the skin. 
Now we would like to say something about 
the behavior of these neoplasms. In the world 
collection, the mesenchymal tumors occurred 
in a younger average age group than the 
epithelial lesions, 35 versus 31 years. These 
mesenchymal tumors occurred relatively early, 
postoperatively, at an average of 21 months 
after transplantation compared to the some-
what longer interval of 35 months with the 
carCInomas. 
A number of epithelial tumors were of low 
grade malignancy and could be cured with 
standard therapy. Of the 44 patients in this 
group, more than half are currently alive in-
cluding almost all those with skin, lip, and 
uterine cervical carcinomas. In contrast, the 
epithelial malignancies within the thorax and 
abdomen tended to be rapidly lethal. Both of 
our patients with tumors in these locations 
have died and the same is probably nearly 
completely true in the world experience. 
Similarly, there has been a dismal prognosis 
with the mesenchymal tumors inasmuch as only 
three of the 32 patients is still living to our 
certain knowledge (one patient each in Denver, 
Galveston, and Israel). All of the kidney reci-
pients in the subgroup of patients who develop-
ed reticulum cell sarcomas died within a short 
time, usually as the direct consequence of the 
tumor. Reticulum cell sarcoma most commonly 
involves the hematopoietic system and invasion 
of the brain in the non-immunosuppressed 
patient is uncommon. Amongst the 21 trans-
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plant reCIpIents with this diagnosis, there was 
invasion of the brain in ten and in seven cases 
the brain was the only organ involved. The 
brain was also involved in other kinds of 
lymphomas. Fig. 2 shows the gross appearance 
of reticulum cell sarcoma in one of our kidney 
patients who died almost 51/2 months after 
transplantation. The liver has been the second 
most commonly involved organ in these patients 
with reticulum cell sarcoma. The patient whose 
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Fig. 2: 
Tumor nodules in the left 
occipital lobe and cerebel-
lum. The flattened gyri rc-
fleet increased intracranial 
pressure caused by rcticulum 
cell sarcoma. 
Fig. 3: 
Disseminated reticulum cell 
sarcoma in a renal homo-
graft recipient in our series. 
This 5 em nodule was one 
of several found in the 
liver. The patient was never 
treated with ALG. 
liver is shown in Fig. 3 died of sarcomatosis 
almost 3 years post-transplantation. 
Etiology 
We would like now to turn to some specific 
questions of the etiology of the de novo 
malignancies in these immunosuppressed reci-
pients, conceding at the outset that the tumors 
did not predate transplantation and that they 
were not systematically transplanted along 
with the organs from donors suffering from 
cancer. Were these neoplasias caused by ALG 
as has sometimes unfortunately been stated? 
The facts are summarized in Table 4. So far, a 
unique contribution of anyone of the indi-
vidual immunosuppressive measures has not 
Table 4: 
Malignant Tumors in Organ Homograft Recipients 
Immunosuppressive Measures 
Azathioprine 
Prednisone 
Antilymphocyte globulin 
Splenectomy 
Thymectomy 
Thoracic duct fistula 
75 cases 
75 cases 
21 casesD~ 
30 cases 
5 cases 
2 cases 
* 2 patients received ALG after the appearance of 
the tumor. 
been evident. All 75 patients in which the 
information about treatment is available re-
ceived azathioprine and prednisone, 30 under-
went splenectomy, and 5 had thymectomy. 
Twentyone received antilymphocyte serum 
(ALS) or globulin (ALG) but in 2 of these 
patients there was evidence of the tumor 
before ALS treatment was begun. Before the 
onset of the diagnosed tumor growth, many 
of the patients had had difficulties with homo-
graft rejection and in an effort to control this 
process had received increased doses of Im-
munosuppressive agents, especially steroids. 
Instead of indicting anyone of the individual 
immunosuppressive agents, the data we have 
collected indicates simply that malignant dis-
ease is a general complication of immuno-
suppressive treatment. Furthermore, its fre-
quency, in our judgment, is apt to reflect the 
effectiveness with which treatment has been 
delivered. A summary statement would then 
be that the malignancies are an effect of 
iatrogenic immunosuppression with a conse-
quent loss of the immunologic surveillance 
mechanism by which tumor mutants are nor-
mally detected and destroyed. 
Fig. 4: 
Pneumoencephalogram in a 20-year-old woman 
who had been treated with renal homotransplanta-
tion a few months previously. Progressive hemi-
paresis had developed postoperatively. A mass was 
found, protruding into the right lateral ventricle. 
This was biopsied with stereotaxic apparatus and 
found to be a lymphoma. 
Acceptance of the surveillance hypothesis as 
the indirect explantation for post-transplanta-
tion neoplasia does not exclude a variety of 
specific etiologic factors which could directly 
cause malignant transformation of cells. These 
could include a toxic effect of the actual 
immunosuppressive agents, carcinogens (such 
as tobacco, ultraviolet light, or irradiation) in 
the environment, or oncogenic viruses. Con-
cerning the last possibility, it is of interest that 
infections by the Herpes family have been very 
common in transplantation recipients. Two hu-
man strains of this virus, the Epstein-Barr and 
Herpes hominis II, have been found to be 
commonly associated with although not neces-
sarily responsible for Burkitt's lymphoma and 
uterine cervical carcinoma respectively. 
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Treatment 
Before closing, it might be worthwhile to say 
something about the treatment of these malig-
nancies in transplant patients. The epithelial 
malignancies of the skin, lip, and uterine cervix 
were successfully treated by standard surgical 
techniques without risking the homografts by 
arbitrary reductions in immunosuppression. 
The "deep" malignancies have not been effecti-
vely treated with this approach and led or 
contributed to death with carcinomas of the 
thoracic and abdominal organs and with 
mesenchymal tumors. In these latter cases, it 
may be advisable to lighten or conceivably 
even stop treatment. The patient shown in 
Fig. 4 is an example. She had a lymphoma of 
the basal diencephalon which was treated with 
local irradiation. In addition, her immuno-
suppression was drastically reduced despite of 
which rejection of the renal homograft did not 
occur. She is in excellent health 5 years after 
transplantation and 41/2 years after the diag-
nosis of the tumor. 
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